Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-grazy-02 PET/CT for Monitoring Immunotherapy in Cancer
NCT07724535Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jun 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
A Phase 2 trial of 18F-grazy-02 in non-small cell lung cancer (NSCLC), melanoma, sponsored by Peking University Cancer Hospital & Institute. Started Jun 2026; status: recruiting.
02
Drugs
18F-grazy-02
03
Conditions
non-small cell lung cancer (NSCLC)melanoma
Beyond the preview
Go deeper on NCT07724535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07724535.